Phathom Pharmaceuticals

Edit info

Founded: 2019

Location: Menlo Park, CA

Employee range: 50 - 200

Clinical stage: COM

Therapy area: H. pylori infection

Drug types: INF, GI, PED

Lead product: Voquezna (Vonoprazan)

Funding: $150M stock May 2023; $182M IPO Oct 2019; $90M May 2019

Investors: Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth

phathompharma.com

linkedin.com

job board

Business:

Novel treatments for gastrointestinal diseases and disorders

Drug notes:

Also NDA errosive GERD, heartburn, Clin3 heartburn in non-erosive GERD, different dosing Clin2 heartburn in non-erosive GERD, Clin2 eosinophilic esophagitis

About:

Phathom Pharmaceuticals is dedicated to improving treatments for gastrointestinal (GI) diseases. They focus on developing innovative therapies for acid-related disorders like ulcers and heartburn. One key area of their research is the development of new proton pump inhibitors – a class of drugs that reduce stomach acid production. While there are existing PPIs on the market, Phathom is investigating more effective and potentially longer-lasting options. This could lead to improved patient outcomes and potentially reduce the need for frequent medication use.